$1.14/ day, billed weekly
Cancel anytime

(Ad-Free, Unlimited access)

NO CREDIT CARD REQUIRED

PSIL

AdvisorShares Psychedelics ETF (PSIL)

$11.27

Delayed price

PASS

BUY Advisory
SELL Advisory (Profit)
SELL Advisory (Loss)

Profit
Loss
Pass (Skip investing)

Time period over

ALL
YEAR
MONTH
WEEK

Upturn Advisory Summary

04/01/2025: PSIL (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

Analysis of Past Performance

Type ETF

Historic Profit -22.58%

Avg. Invested days 24

Today’s Advisory PASS

Upturn Star Rating

Upturn Advisory Performance

2.0

ETF Returns Performance

1.0

Profits based on simulation

Last Close 04/01/2025

Key Highlights

Volume (30-day avg) 8716	Beta 0.72	52 Weeks Range 7.01 - 15.73	Updated Date 04/2/2025
52 Weeks Range 7.01 - 15.73	Updated Date 04/2/2025

Upturn AI SWOT

AdvisorShares Psychedelics ETF

ETF Overview

Overview

The AdvisorShares Psychedelics ETF (PSIL) is designed to invest in companies involved in the legal psychedelics industry, focusing on pharmaceutical, biotechnology, and other related sectors.

Reputation and Reliability

AdvisorShares is known for thematic ETFs and actively managed funds. Reputation is moderate; reliability depends on market sector performance.

Management Expertise

AdvisorShares management team has experience in various niche investment strategies, including cannabis and psychedelics.

Investment Objective

Goal

To seek long-term capital appreciation by investing in companies deriving a significant portion of their net revenue from the psychedelics industry.

Investment Approach and Strategy

Strategy: Actively managed, not designed to track a specific index. Focuses on identifying companies with high growth potential within the psychedelics sector.

Composition Primarily invests in stocks of companies involved in psychedelic drug development, research, and related activities.

Market Position

Market Share: PSIL holds a notable but not dominant share of the emerging psychedelics ETF market.

Total Net Assets (AUM): 19240000

Competitors

Key Competitors

Competitive Landscape

The psychedelics ETF market is nascent and competitive. PSIL's active management offers potential upside, but also higher risk compared to passive strategies. Advantage is that this is a pioneering ETF. Disadvantage is it's higher expense ratio.

Financial Performance

Historical Performance: Historical performance data not available, as PSIL is a new fund.

Benchmark Comparison: No specific benchmark, as PSIL targets a unique, emerging sector. Performance comparison is against broader market indices or similar thematic ETFs, if any exist.

Expense Ratio: 0.75

Liquidity

Average Trading Volume

Average trading volume is moderate, reflecting the niche focus of the ETF.

Bid-Ask Spread

The bid-ask spread may be wider than more liquid ETFs, reflecting the emerging nature of the sector.

Market Dynamics

Market Environment Factors

Regulatory changes, scientific advancements, and shifts in public perception regarding psychedelics are key market environment factors. Broader stock market factors also impact performance.

Growth Trajectory

Growth depends on the pace of regulatory approval, clinical trial successes, and market adoption of psychedelic therapies. Strategy and holdings will likely evolve alongside the industry.

Moat and Competitive Advantages

Competitive Edge

PSIL's competitive advantage lies in its active management team's expertise in identifying promising companies within the emerging psychedelics industry. The team's specific focus on a particular sector may lead to outperformance in the long term. Also, this is a pioneer fund. It has first-mover advantage. Active management offers the opportunity to adjust to market changes more quickly.

Risk Analysis

Volatility

Volatility is expected to be high due to the speculative nature of the psychedelics industry and the small size of the underlying companies.

Market Risk

Market risk includes regulatory setbacks, clinical trial failures, competition from alternative treatments, and changes in investor sentiment toward the psychedelics sector.

Investor Profile

Ideal Investor Profile

The ideal investor is risk-tolerant, has a long-term investment horizon, and is interested in the potential of the psychedelics industry. High risk tolerance is required.

Market Risk

Best suited for long-term investors willing to accept high volatility and uncertainty. Not suitable for risk-averse investors or those seeking short-term gains.

Summary

The AdvisorShares Psychedelics ETF (PSIL) offers exposure to the emerging psychedelics industry. Its active management and narrow focus provide potential for high growth, but also high volatility. It is best suited for risk-tolerant investors with a long-term perspective. Performance is dependent on regulatory approvals, clinical trial successes, and market adoption. Consider your risk tolerance before investing.

Similar Companies

CNBS

Amplify Seymour Cannabis ETF

$17.49

ETF

ETF

PASS

Sources and Disclaimers

Data Sources:

AdvisorShares Website
ETF.com
Morningstar
SEC Filings

Disclaimers:

Past performance is not indicative of future results. Investing in ETFs involves risk, including the potential loss of principal. Psychedelics sector investments are highly speculative.

Upturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About AdvisorShares Psychedelics ETF

Exchange NYSE ARCA	Headquaters -
IPO Launch date -	CEO -
Sector -	Industry -	Full time employees -	Website
Full time employees -	Website

The fund is an actively managed ETF that seeks to achieve its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that derive at least 50% of their net revenue from or devote 50% of their assets to psychedelic drugs and derivatives that have economic characteristics similar to such securities. The fund primarily invests in publicly listed life sciences companies focused on psychedelic medicines as well as other companies with activities in the psychedelics business. The fund is non-diversified.

https://www.upturn.io

Disclosure Privacy Policy Terms of Use Sitemap Contact Us

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.